Skip to content

Depression research published in 2023

Page 8 of 24: studies 141 to 160 of 466, newest first. Back to the depression overview

Studies

The impact of a mindfulness-based stress reduction training program on depression, anxiety, and stress in Moroccan nurses

Kontakt August 15, 2023 Jamal Ksiksou, Lhoussaine Maskour, Smail Alaoui 5 citations

Pozadí: Tato studie zkoumá dopad tréninkového programu zaměřeného na snižování stresu, deprese a úzkosti na základě všímavosti u zdravotních sester v Maroku. Metody: Účastníci byli vybráni z nemocnice v provincii Tetouan v Maroku. Jednalo se o 80 nemocničních sester, 59 žen a 21 mužů. Byli náhodně rozděleni do intervenční skupiny a kontrolní skupiny, v každé...

Major depressive disorder diagnosis from electroencephalogram data and potential treatment with dimethyltryptamine

International Advanced Researches and Engineering Journal August 15, 2023 Sushmit Jahan 1 citation

In recent times, there has been increasing interest in utilizing EEG-based techniques for studying Major Depressive Disorder as a dynamic method. Although it is frequently used for identifying depression, the method is still difficult to interpret. The conventional treatment of MDD involves medications such as Selective Serotonin Reuptake Inhibitors, which often have adverse effects. On the...

Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy

Psychiatric News August 15, 2023 Nick Zagorski 3 citations

The country is the first to make psilocybin and MDMA available for medical use by prescription as part of a psychedelic-assisted psychotherapy regimen. In a move that excited some and concerned others, Australia’s Therapeutic Goods Administration (TGA) earlier this year approved the use of MDMA and psilocybin as adjuncts in the treatment of posttraumatic stress disorder (PTSD) and...

DOI: 10.1176/appi.pn.2023.09.9.20 (opens in new tab) Depression economics Psychotherapist Clinical psychology

The use of psilocybin in the treatment of psychiatric disorders – review

Journal of Education, Health and Sport August 15, 2023 Justyna Woźniak, Rafał Bogacz, Magdalena Gaik et al.

Introduction: The word “psychedelic” derives from the Greek language and can be loosely translated as “mind manifesting” which is to convey that these substances allow the mind to unleash its hidden potential. Psilocybin is considered to be a “classic psychedelic” and is most commonly found in the form of so-called “magic mushrooms”. Due to its unique properties psilocybin has been used during...

Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy.

The Journal of Clinical Psychiatry August 14, 2023 Michael E. Thase 9 citations

Among the greatest unmet needs in major depressive disorder (MDD) is a lack of effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications. After decades of muted progress, optimism regarding the future of MDD therapy rose after scientists serendipitously uncovered the antidepressant effects of ketamine. The discovery of ketamine's...

DOI: 10.4088/jcp.mulmdd3048sho (opens in new tab) Full text (opens in new tab) Mental-health Depression-treatment Drug-therapy Medical-breakthroughs +1

The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design

Trials August 13, 2023 Irina Falkenberg, Florian Bitsch, Wei Liu et al. 4 citations

Abstract Background Major depressive disorder (MDD) is a highly prevalent (8–15%), severely disabling disorder and is associated with enormous socioeconomic impact. Antidepressant medication for the treatment of MDD has proven effective in RCTs; however, placebo response is also substantial. Given the potential benefits of modulating the placebo response in patient care and pharmacological...

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.

BMC Psychiatry August 11, 2023

Abstract: Background: Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses of two pivotal phase 3 studies, ASPIRE I and II, remission rates were consistently higher among patients with MDD with active suicidality who...

Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report.

Bipolar Disorders August 10, 2023

Renato de Filippis received travel grants and/or speaker/consultant fees from Janssen-Cilag. Pasquale De Fazio declares that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please...

Effectiveness and Changes in Brain Functions by an Occupational Therapy Program Incorporating Mindfulness in Outpatients with Anxiety and Depression: A Randomized Controlled Trial.

Neuropsychobiology August 10, 2023 Atsuko Yamamoto, Banri Tsukuda, Shota Minami et al.

Introduction: This study examined the efficacy of an 8-week occupational therapy program incorporating mindfulness (MOT) as a form of psychiatric rehabilitation to ameliorate residual social and occupational impairment in patients with anxiety disorders and depression. The objective was to evaluate the effects of MOT on their personal well-being and to assess the impact of MOT on brain function...

Evaluating the Effect of Mindfulness Group Training on Anxiety, Stress, and Depression in Mothers with Children with Learning Disorder: A Randomized Clinical Trial

Avicenna Journal of Nursing and Midwifery Care August 9, 2023 Elham Hasannia, Mohammad Reza Sheikhi, Mohammad Ali Soleimani et al.

Background and Objective: The present study aimed to determine the effect of mindfulness group training on anxiety, stress, and depression in mothers with children with learning disabilities. Materials and Methods: A clinical trial was performed with the participation of 60 mothers with children suffering from learning disabilities in 2021 in Qazvin City, Iran. The participants were divided...

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.

CNS Drugs August 9, 2023 Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi et al.

Background: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK...

Psilocybin's Emerging Role in Combating Depressive Disorder

Journal of Education, Health and Sport August 8, 2023 Anna Jaremek, Joanna Kępa, Norbert Kandefer et al.

In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment. Depression, a widespread psychological malady affecting countless individuals across the globe, often proves stubborn against existing treatment modalities, necessitating exploration...

Suicidal ideation and suicide attempt following ketamine prescription in patients with treatment-resistant depression: a nation-wide cohort study

Research Square August 7, 2023 Rong Xu, Yiheng Pan, Maria P Gorenflo et al. preprint

Abstract Ketamine, including esketamine, is an effective treatment for patients with treatment-resistant depression (TRD); however, its long-term efficacy in real-world populations remains poorly characterized. This is a retrospective cohort study using TriNetX US Collaborative Network, a platform aggregating electronic health records (EHRs) data from 93 million patients from 56 health care...

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

European Neuropsychopharmacology August 7, 2023 Natacha Perez, Florent Langlest, Luc Mallet et al. 85 citations

Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD 42022220190) multiple electronic databases were searched from their inception until February 2023, to identify...

A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression

International Journal of Molecular Sciences August 7, 2023 Alexander Pilozzi, Simmie Foster, David Mischoulon et al. 16 citations

Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using...

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.

Current Medical Research and Opinion August 3, 2023

OBJECTIVE: To describe access and real-world use patterns of esketamine nasal spray among adults with treatment-resistant depression (TRD) with private or public insurance. METHODS: Adults with ≥1 claim for esketamine nasal spray were selected from Clarivate's Real World Data product (January 2016-March 2021). Patients with evidence of TRD initiating esketamine (index date) after 05 March 2019...

Mindfulness-Training in Preadolescents in School: The Role of Emotionality, EEG in Theta/Beta Bands, Creativity and Attention.

Child Psychiatry and Human Development August 2023 Nathaniel A. Shanok, Camila Saldias-Manieu, Krystal D. Mize et al.

Mindfulness meditation is a means of increasing awareness of the present moment. Mindfulness Mediation Interventions (MMI) positively impact psychological functioning, yet the neurocognitive mechanisms that mediate these effects have been less well-defined. Here, the primary aim was to evaluate whether the effects of a 10-week MMI were mediated by changes in attention and creativity...

Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial.

JAMA Network Open August 1, 2023 Chunfeng Xiao, Jia Zhou, Anning Li et al.

Importance: Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies. Objective: To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral...

Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion.

Journal of Psychopharmacology August 2023 Wei-Chen Lin, Tung-Ping Su, Cheng-Ta Li et al.

Whether pretreatment working memory and response inhibition function are associated with the rapid and sustained antisuicidal effect of low-dose ketamine among patients with treatment-resistant depression (TRD) and strong suicidal ideation is unclear. We enrolled 65 patients with TRD, comprising 33 who received a single infusion of 0.5 mg/kg ketamine and 32 who received a placebo infusion. The...

DOI: 10.1177/02698811231182107 (opens in new tab) Full text (opens in new tab) Ketamine Antisuicidal effect Response inhibition Working memory